Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
Chou A , Froio D , Nagrial AM , Parkin A , Murphy KJ , Chin VT , Wohl D , Steinmann A , Stark R , Drury A , Walters SN , Vennin C , Burgess A , Pinese M , Chantrill LA , Cowley MJ , Molloy TJ , , Waddell N , Johns A , Grimmond SM , Chang DK , Biankin AV 
Gut.2017 Oct 28 ; ():.
PubMedで表示
Google翻訳で開く
(40view , 0users)
Extensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA), few effective therapies and high mortality make this disease a prime model for advancing development of tailored therapies. The p16-cyclin D-cyclin-dependent kinase 4/6-retinoblastoma (RB) protein (CDK4) pathway, regulator of cell proliferation, is deregulated in PDA. Our aim was to develop a novel personalised treatment strategy for PDA based on targeting CDK4.
PMID: 29080858 [PubMed - as supplied by publisher]
PMID: 29080858 [PubMed - as supplied by publisher]
関連論文
- Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
- Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
- Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
- [Review] Targeting CDK4/6 in patients with cancer.